Lowest Price Guaranteed
Pages
335
Last Updated
April 2026
View Count
20551
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Antibody Drug Conjugates
6.2.1. Components of an ADC
6.2.1.1. Antibody
6.2.1.2. Cytotoxin
6.2.1.3. Linker
6.3. Advantages of ADCs over Conventional Therapeutics
6.4. ADC Linker Technologies
6.4.1. Non-cleavable Linkers
6.4.2. Cleavable Linkers
6.5. ADC Conjugation Technologies
6.5.1. Chemical Conjugation
6.5.2. Enzymatic Conjugation
6.6. Future Perspective
7. MARKET LANDSCAPE: ADC CONJUGATION AND LINKER TECHNOLOGIES
7.1. Chapter Overview
7.2. ADC Conjugation and Linker Technologies: Overall Market Landscape
7.2.1. Analysis by Type of Technology
7.2.2. Analysis by Availability of Licensing
7.2.3. Analysis by Generation of Technology
7.2.4. Analysis by Type of Conjugation
7.2.5. Analysis by Site Specificity
7.2.6. Analysis by Drug Antibody Ratio (DAR)
7.2.7. Analysis by Conjugation Chemistry
7.2.8. Analysis by Conjugation Site
7.2.9. Analysis by Type of Linker
7.3. ADC Conjugation and Linker Technology Providers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Year of Establishment and Location of Headquarters
8. TECHNOLOGY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. ADC Technologies: Technology Competitiveness Analysis
8.4.1. Technologies Offered by Providers based in North America (Peer Group I)
8.4.2. Technologies Offered by Providers based in Europe (Peer Group II)
8.4.3. Technologies Offered by Providers based in Asia-Pacific (Peer Group III)
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. ADC Technology Developers Headquartered in North America
9.2.1. Ajinomoto Bio-Pharma Services
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. Technology Portfolio
9.2.1.4. Recent Developments and Future Outlook
9.2.2. Catalent Biologics
9.2.2.1. Company Overview
9.2.2.2. Financial Information
9.2.2.3. Technology Portfolio
9.2.2.4. Recent Developments and Future Outlook
9.2.3. Mersana Therapeutics
9.2.3.1. Company Overview
9.2.3.2. Financial Information
9.2.3.3. Technology Portfolio
9.2.3.4. Recent Developments and Future Outlook
9.2.4. Sutro Biopharma
9.2.4.1. Company Overview
9.2.4.2. Financial Information
9.2.4.3. Technology Portfolio
9.2.4.4. Recent Developments and Future Outlook
9.3. ADC Technology Developers Headquartered in Europe
9.3.1. Antikor Biopharma
9.3.1.1. Company Overview
9.3.1.2. Technology Portfolio
9.3.1.3. Recent Developments and Future Outlook
9.3.2. Debiopharm
9.3.2.1. Company Overview
9.3.2.2. Technology Portfolio
9.3.2.3. Recent Developments and Future Outlook
9.3.3. Heidelberg Pharma
9.3.3.1. Company Overview
9.3.3.2. Financial Information
9.3.3.3. Technology Portfolio
9.3.3.4. Recent Developments and Future Outlook
9.3.4. Iksuda Therapeutics
9.3.4.1. Company Overview
9.3.4.2. Technology Portfolio
9.3.4.3. Recent Developments and Future Outlook
9.3.5. NBE-Therapeutics
9.3.5.1. Company Overview
9.3.5.2. Financial Information
9.3.5.3. Technology Portfolio
9.3.5.4. Recent Developments and Future Outlook
9.3.6. Synaffix (a Lonza Company)
9.3.6.1. Company Overview
9.3.6.2. Financial Information
9.3.6.3. Technology Portfolio
9.3.6.4. Recent Developments and Future Outlook
9.4. ADC Technology Developers Headquartered in Asia-Pacific and Rest of the World
9.4.1. Alteogen
9.4.1.1. Company Overview
9.4.1.2. Technology Portfolio
9.4.1.3. Recent Developments and Future Outlook
9.4.2. LigaChem Biosciences
9.4.2.1. Company Overview
9.4.2.2. Technology Portfolio
9.4.2.3. Recent Developments and Future outlook
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. ADC Conjugation and Linker Technologies: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis by Type of Patent and Publication Year
10.3.3. Analysis by Patent Application Year
10.3.4. Analysis by Patent Jurisdiction
10.3.5. Analysis by CPC Symbols
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Industry Players: Analysis by Number of Patents
10.3.8. Leading Non-Industry Players: Analysis by Number of Patents
10.4. Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. Patent Valuation
10.6. Leading Patents by Number of Citations
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. ADC Linker and Conjugation Technologies: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year of Partnership and Type of Partnership
11.3.4. Analysis by Purpose of Partnership
11.3.5. Analysis by Type of Partner
11.3.6. Most Active Players: Analysis by Number of Partnerships
11.3.7. Most Popular Technologies: Analysis by Number of Partnerships
11.4. Analysis by Geography
11.4.1. Local and International Agreements
11.4.2. Intercontinental and Intracontinental Agreements
12. BUSINESS MODEL ANALYSIS
12.1. Chapter Overview
12.2. Business Models
12.3. ADC Technology Providers: Business Model Analysis
12.3.1. Analysis by Purpose of Partnership
12.3.2. Analysis by Year of Partnership and Purpose of Partnership
12.3.3. Analysis by Type of Business Model Adopted
12.3.4. Analysis by Deal Value
12.3.5. Analysis by Type of Business Model Adopted and Deal Value
12.4. Most Active Players: Analysis by Number of Partnerships
12.4.1. Lonza
12.4.1.1. Analysis by Purpose of Partnership
12.4.1.2. Analysis of Year of Partnership and Business Model Adopted
12.4.2. LigaChem Biosciences
12.4.2.1. Analysis by Purpose of Partnership
12.4.2.2. Analysis by Year of Partnership and Business Model Adopted
12.4.3. Debiopharm
12.4.3.1. Analysis by Purpose of Partnership
12.4.3.2. Analysis by Year of Partnership and Business Model Adopted
12.4.4. Duality Biologics
12.4.4.1. Analysis by Year of Partnership and Business Model Adopted
12.4.5. IntoCell
12.4.5.1. Analysis by Purpose of Partnership
12.4.5.2. Analysis by Year of Partnership and Business Model Adopted
12.5. Concluding Remarks
13. LIKELY PARTNER ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Key Parameters
13.3. Scope and Methodology
13.4. Potential Strategic Partners in North America
13.4.1. Most Likely Partners
13.4.2. Likely Partners
13.4.3. Less Likely Partners
13.5. Potential Strategic Partners in Europe
13.5.1. Most Likely Partners
13.5.2. Likely Partners
13.5.3. Less Likely Partners
13.6. Potential Strategic Partners in Asia-Pacific and Rest of the World
13.6.1. Most Likely Partners
13.6.2. Likely Partners
13.6.3. Less Likely Partners
14. BRAND POSITIONING ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Key Parameters
14.4. Brand Positioning Matrix: ADC Technology Providers
14.4.1. Brand Positioning Matrix: Byondis
14.4.2. Brand Positioning Matrix: Catalent Biologics
14.4.3. Brand Positioning Matrix: Creative Biolabs
14.4.4. Brand Positioning Matrix: Duality Biologics
14.4.5. Brand Positioning Matrix: GeneQuantum Healthcare
14.4.6. Brand Positioning Matrix: Mersana Therapeutics
14.4.7. Brand Positioning Matrix: OBI Pharma
14.4.8. Brand Positioning Matrix: Synaffix
14.4.9. Brand Positioning Matrix: Tubulis
14.4.10. Brand Positioning Matrix: Zymeworks
15. CASE STUDY: ANTIBODY DRUG CONJUGATES
15.1. Chapter Overview
15.2. Antibody-Drug Conjugates: Overall Market Landscape
15.2.1. Analysis by Stage of Development
15.2.2. Analysis by Target Indication
15.2.3. Analysis by Therapeutics Area
15.2.4. Analysis by Line of Treatment
15.2.5. Analysis by Dosing Frequency
15.2.6. Analysis by Type of Therapy
15.2.7. Analysis by Target Antigen
15.2.8. Analysis by Antibody Isotypes
15.2.9. Analysis by Type of Linker (Cleavable / Non-cleavable)
15.2.10. Analysis by Payload / Cytotoxin / Warhead
15.2.11. Analysis by Type of Payload
15.3. Antibody-Drug Conjugate Developers: Overall Landscape
15.3.1. Analysis by Year of Establishment
15.3.2. Analysis by Company Size
15.3.3. Analysis by Location of Headquarters
15.3.4. Most Active Player: Analysis by Number of Therapies
16. MARKET IMPACT ANALYSIS
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion
17. GLOBAL ADC TECHNOLOGY MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global ADC Technology Market: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
17.3.1. Roots Analysis Perspective on Market Growth
17.3.2. Scenario Analysis
17.3.2.1. Conservative Scenario
17.3.2.2. Optimistic Scenario
17.4. Key Market Segmentations
18. ADC TECHNOLOGY MARKET, BY GENERATION OF TECHNOLOGY
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. ADC Technology Market: Distribution by Generation of Technology
18.3.1. ADC Technology Market for Next-Generation: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
18.3.2. ADC Technology Market for Third-Generation: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
18.3.3. ADC Technology Market for Second-Generation: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
18.3.4. ADC Technology Market for First-Generation: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
18.4. Data Triangulation and Validation
19. ADC TECHNOLOGY MARKET, BY TYPE OF CONJUGATION
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. ADC Technology Market: Distribution by Type of Conjugation
19.3.1. ADC Technology Market for Chemical Conjugation: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
19.3.2. ADC Technology Market for Chemoenzymatic Conjugation: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
19.3.3. ADC Technology Market for Enzymatic Conjugation: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
19.4. Data Triangulation and Validation
20. ADC TECHNOLOGY MARKET, BY TYPE OF LINKER
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. ADC Technology Market: Distribution by Type of Linker
20.3.1. ADC Technology Market for Cleavable Linker: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
20.3.2. ADC Technology Market for Non-cleavable Linker: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
20.4. Data Triangulation and Validation
21. ADC TECHNOLOGY MARKET, BY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. ADC Technology Market: Distribution by Geographical Regions
21.3.1. ADC Technology Market in North America: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
21.3.2. ADC Technology Market in Europe: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
21.3.3. ADC Technology Market in Asia-Pacific: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
21.3.4. ADC Technology Market in Latin America: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
21.3.5. ADC Technology Market in Middle East and North Africa: Historical Trends (since 2025) and Forecasted Estimates (till 2040)
21.4. Data Triangulation and Validation
**Detailed information on cross sectional analysis is available in the Excel Data Packs shared along with the report**
22. CONCLUSION
23. EXECUTIVE INSIGHTS
23.1. Chapter Overview
23.2. Company A
23.2.1. Company Snapshot
23.2.2. Interview Transcript: §
23.3. Company B
23.3.1. Company Snapshot
23.3.2. Interview Transcript: Associate General Manager
23.4. Company C
23.4.1. Company Snapshot
23.4.2. Interview Transcript: Scientist II
23.5. Company D
23.5.1. Company Snapshot
23.5.2. Interview Transcript: Co-Founder and Chief Scientific Officer
23.6. Company E
23.6.1. Company Snapshot
23.6.2. Interview Transcript: Head of Strategy and Business Development
23.7. Company F
23.7.1. Company Snapshot
23.7.2. Interview Transcript: Board Member
23.8. Company G
23.8.1. Company Snapshot
23.8.2. Interview Transcript: General Manager, Research and Development, Director of ADC Process Development and Tech Transfer
23.9. Company H
23.9.1. Company Snapshot
23.9.2. Interview Transcript: Head of Research and Development
23.10. Company I
23.10.1. Company Snapshot
23.10.2. Interview Transcript: Former Chief Business Officer
23.11. Company J
23.11.1. Company Snapshot
23.11.2. Interview Transcript: Chief Executive Officer
23.12. Company K
23.12.1. Company Snapshot
23.12.2. Interview Transcript: Chief Scientific Officer
24. APPENDIX 1: TABULATED DATA
25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 Components of ADCs
Figure 6.2 Types of Linkers
Figure 7.1 ADC Technologies: Distribution by Type of Technology
Figure 7.2 ADC Technologies: Distribution by Availability of Licensing
Figure 7.3 ADC Technologies: Distribution by Generation of Technology
Figure 7.4 ADC Technologies: Distribution by Type of Conjugation
Figure 7.5 ADC Technologies: Distribution by Site Specificity
Figure 7.6 ADC Technologies: Distribution by Drug Antibody Ratio
Figure 7.7 ADC Technologies: Distribution by Conjugation Chemistry
Figure 7.8 ADC Technologies: Distribution by Conjugation Site
Figure 7.9 ADC Technologies: Distribution by Type of Linker
Figure 7.10 ADC Technology Providers: Distribution by Year of Establishment
Figure 7.11 ADC Technology Providers: Distribution by Company Size
Figure 7.12 ADC Technology Providers: Distribution by Location of Headquarters
Figure 7.13 ADC Technology Providers: Distribution by Year of Establishment and Location of Headquarters
Figure 8.1 Technology Competitiveness Analysis: Distribution of Technologies Offered by Players based in North America (Peer Group I)
Figure 8.2 Technology Competitiveness Analysis: Distribution of Technologies Offered by Players based in Europe (Peer Group II)
Figure 8.3 Technology Competitiveness Analysis: Distribution of Technologies Offered by Players based in Asia-Pacific (Peer Group III)
Figure 9.1 Ajinomoto Bio-Pharma Services: Annual Revenues, FY 2021-H1 FY 2025 (JPY Billion)
Figure 9.2 Novo Nordisk (parent company of Catalent Biologics): Annual Revenues, FY 2021-9M FY 2025 (DKK Billion)
Figure 9.3 Mersana Therapeutics: Annual Revenues, FY 2021-9M FY 2025 (USD Million)
Figure 9.4 Sutro Biopharma: Annual Revenues, FY 2021-9M FY 2025 (USD Million)
Figure 9.5 Heidelberg Pharma: Annual Revenues, FY 2021- 9M FY 2025 (EUR Million)
Figure 9.6 Boehringer Ingelheim (parent company of NBE Therapeutics): Annual Revenues, FY 2021-H1 FY 2025 (EUR Billion)
Figure 9.7 Lonza (parent company of Synaffix): Annual Revenues, FY 2021-9M FY 2025 (CHF Billion)
Figure 9.8 LigaChem Biosciences: Annual Revenues, FY 2021-9M FY 2025 (KRW Billion)
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Publication Year, 2021-2025
Figure 10.3 Patent Analysis: Cumulative Distribution by Application Year, Pre-2019-2025
Figure 10.4 Patent Analysis: Distribution of Type of Patent by Publication Year, 2021-2025
Figure 10.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 10.6 Patent Analysis: Distribution by CPC Symbols
Figure 10.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 10.8 Leading Industry Players: Distribution by Number of Patents
Figure 10.9 Leading Patent Assignees: Distribution by Number of Patents
Figure 10.10 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 10.11 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 10.12 Patent Analysis: Distribution by Patent Age
Figure 10.13 ADC Technologies: Patent Valuation
Figure 11.1 Partnerships and Collaborations: Cumulative year-wise Trend, 2021-2025 (till November)
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership, 2021-2025 (till November)
Figure 11.4 Most Active Players: Distribution by Number of Partnerships
Figure 11.5 Most Popular Technologies: Distribution by Number of Partnerships
Figure 11.6 Partnerships and Collaborations: Local and International Agreements
Figure 11.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 12.1 Business Models Analysis: Distribution by Purpose of Partnership
Figure 12.2 Business Models Analysis: Distribution by Year and Purpose of Partnership, 2021-2025 (till November)
Figure 12.3 Business Models Analysis: Distribution by Type of Business Model Adopted
Figure 12.4 Business Models Analysis: Distribution by Deal Value
Figure 12.5 Business Models Analysis: Distribution by Type of Business Model Adopted and Deal Value
Figure 12.6 Most Active Players: Analysis by Number of Partnerships
Figure 12.7 Lonza: Distribution by Purpose of Partnership
Figure 12.8 Lonza: Distribution by Year of Partnership and Business Model Adopted
Figure 12.9 LigaChem Biosciences: Distribution by Purpose of Partnership
Figure 12.10 LigaChem Biosciences: Distribution by Year of Partnership and Business Model Adopted
Figure 12.11 Debiopharm: Distribution by Purpose of Partnership
Figure 12.12 Debiopharm: Distribution by Year of Partnership and Business Model Adopted
Figure 12.13 Duality Biologics: Distribution by Year of Partnership and Business Model Adopted
Figure 12.14 IntoCell: Distribution by Purpose of Partnership
Figure 12.15 IntoCell: Distribution by Year of Partnership and Business Model Adopted
Figure 14.1 Brand Positioning Analysis: Competitive Advantage
Figure 14.2 Brand Positioning Matrix: Byondis
Figure 14.3 Brand Positioning Matrix: Catalent Biologics
Figure 14.4 Brand Positioning Matrix: Creative Biologics
Figure 14.5 Brand Positioning Matrix: Duality Biologics
Figure 14.6 Brand Positioning Matrix: GeneQuantum Healthcare
Figure 14.7 Brand Positioning Matrix: Mersana Therapeutics
Figure 14.8 Brand Positioning Matrix: OBI Pharma
Figure 14.9 Brand Positioning Matrix: Synaffix
Figure 14.10 Brand Positioning Matrix: Tubulis
Figure 14.11 Brand Positioning Matrix: Zymeworks
Figure 15.1 Antibody-Drug Conjugates: Distribution by Stage of Development
Figure 15.2 Antibody-Drug Conjugates: Distribution by Target Indication
Figure 15.3 Antibody-Drug Conjugates: Distribution by Therapeutic Area
Figure 15.4 Antibody-Drug Conjugates: Distribution by Line of Treatment
Figure 15.5 Antibody-Drug Conjugates: Distribution by Dosing Frequency
Figure 15.6 Antibody-Drug Conjugates: Distribution by Type of Therapy
Figure 15.7 Antibody-Drug Conjugates: Distribution by Target Antigen
Figure 15.8 Antibody-Drug Conjugates: Distribution by Antibody Isotypes
Figure 15.9 Antibody-Drug Conjugates: Distribution by Type of Linker (Cleavable/Non-Cleavable)
Figure 15.10 Antibody-Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
Figure 15.11 Antibody-Drug Conjugates: Distribution by Type of Payload
Figure 15.12 Antibody-Drug Conjugate Developers: Distribution by Year of Establishment
Figure 15.13 Antibody-Drug Conjugate Developers: Distribution by Company Size
Figure 15.14 Antibody-Drug Conjugate Developers: Distribution by Location of Headquarters (Region)
Figure 15.15 Antibody-Drug Conjugate Developers: Distribution by Location of Headquarters (Country)
Figure 15.16 Most Active Players: Distribution by Number of Antibody-Drug Conjugates
Figure 17.1 Licensing Agreements: Distribution of Financial Components
Figure 17.2 Global ADC Technology Market, Historical Trends (Since 2025) and Forecasted Estimates (Till 2040): Base Scenario (USD Billion)
Figure 17.3 Global ADC Technology Market, Historical Trends (Since 2025) and Forecasted Estimates (Till 2040): Conservative Scenario (USD Billion)
Figure 17.4 Global ADC Technology Market, Historical Trends (Since 2025) and Forecasted Estimates (Till 2040): Optimistic Scenario (USD Billion)
Figure 18.1 ADC Technology Market: Distribution by Generation of Technology
Figure 18.2 ADC Technology Market for Next-Generation Technologies: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 18.3 ADC Technology Market for Third-Generation Technologies: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 18.4 ADC Technology Market for Second-Generation Technologies: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 18.5 ADC Technology Market for First-Generation Technologies: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 19.1 ADC Technology Market: Distribution by Type of Conjugation
Figure 19.2 ADC Technology Market for Chemical Conjugation: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 19.3 ADC Technology Market for Chemoenzymatic Conjugation: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 19.4 ADC Technology Market for Enzymatic Conjugation: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 20.1 ADC Technology Market: Distribution by Type of Linker
Figure 20.2 ADC Technology Market for Cleavable Linkers: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 20.3 ADC Technology Market for Non-Cleavable Linkers: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 21.1 ADC Technology Market: Distribution by Geographical Regions
Figure 21.2 ADC Technology Market in North America: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 21.3 ADC Technology Market in Europe: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 21.4 ADC Technology Market in Europe: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 21.5 ADC Technology Market in Asia-Pacific: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 21.6 ADC Technology Market in Latin America: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 21.7 ADC Technology Market in Middle East and North Africa: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Figure 22.1 Conclusion: Market Landscape
Figure 22.2 Conclusion: Market Trends
Figure 22.3 Conclusion: Market Forecast and Opportunity Analysis
Table 6.1 Commonly Used Cytotoxins in ADC Therapeutics
Table 6.2 OEB Bands: Guidelines by SafeBridge Consultants
Table 7.1 ADC Technologies: Information on Type of Technology, Status of Technology, Availability of Licensing, and Generation of Technology
Table 7.2 ADC Technologies: Information on Type of Conjugation, Site Specificity, and Drug Antibody Ratio
Table 7.3 ADC Technologies: Information on Conjugation Chemistry, Conjugation Site, and Type of Linker
Table 7.4 List of ADC Conjugation and Linker Technology Providers
Table 9.1 ADC Linkers and Conjugation Technologies: List of Companies Profiled
Table 9.2 Ajinomoto Bio-Pharma Services: Company Overview
Table 9.3 Ajinomoto Bio-Pharma Services: Technology Portfolio
Table 9.4 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
Table 9.5 Catalent Biologics: Company Overview
Table 9.6 Catalent Biologics: Technology Portfolio
Table 9.7 Catalent Biologics: Antibody Drug Conjugates Portfolio
Table 9.8 Catalent Biologics: Recent Developments and Future Outlook
Table 9.9 Mersana Therapeutics: Company Overview
Table 9.10 Mersana Therapeutics: Technology Portfolio
Table 9.11 Mersana Therapeutics: Antibody Drug Conjugates Portfolio
Table 9.12 Mersana Therapeutics: Recent Developments and Future Outlook
Table 9.13 Sutro Biopharma: Company Overview
Table 9.14 Sutro Biopharma: Technology Portfolio
Table 9.15 Sutro Biopharma: Antibody Drug Conjugates Portfolio
Table 9.16 Sutro Biopharma: Recent Developments and Future Outlook
Table 9.17 Antikor Biopharma: Company Overview
Table 9.18 Antikor Biopharma: Technology Portfolio
Table 9.19 Antikor Biopharma: Antibody Drug Conjugates Portfolio
Table 9.20 Debiopharm: Company Overview
Table 9.21 Debiopharm: Technology Portfolio
Table 9.22 Debiopharm: Antibody Drug Conjugates Portfolio
Table 9.23 Debiopharm: Recent Developments and Future Outlook
Table 9.24 Heidelberg Pharma: Company Overview
Table 9.25 Heidelberg Pharma: Technology Portfolio
Table 9.26 Heidelberg Pharma: Antibody Drug Conjugates Portfolio
Table 9.27 Heidelberg Pharma: Recent Developments and Future Outlook
Table 9.28 Iksuda Therapeutics: Company Overview
Table 9.29 Iksuda Therapeutics: Technology Portfolio
Table 9.30 Iksuda Therapeutics: Antibody Drug Conjugates Portfolio
Table 9.31 Iksuda Therapeutics: Recent Developments and Future Outlook
Table 9.32 NBE Therapeutics: Company Overview
Table 9.33 NBE Therapeutics: Technology Portfolio
Table 9.34 NBE Therapeutics: Antibody Drug Conjugates Portfolio
Table 9.35 NBE Therapeutics: Recent Developments and Future Outlook
Table 9.36 Synaffix: Company Overview
Table 9.37 Synaffix: Technology Portfolio
Table 9.38 Synaffix: Recent Developments and Future Outlook
Table 9.39 Catalent Biologics: Company Overview
Table 9.40 Alteogen: Technology Portfolio
Table 9.41 Alteogen: Antibody Drug Conjugates Portfolio
Table 9.42 LigaChem Biosciences: Company Overview
Table 9.43 LigaChem Biosciences: Technology Portfolio
Table 9.44 LigaChem Biosciences: Antibody Drug Conjugates Portfolio
Table 9.45 LigaChem Biosciences: Recent Developments and Future Outlook
Table 10.1 Patent Analysis: Top CPC Sections
Table 10.2 Patent Analysis: Top CPC Symbols
Table 10.3 Patent Analysis: Top CPC Codes
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 10.6 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 11.1 ADC Technologies: Partnerships and Collaborations
Table 12.1 ADC Technology Providers: Information on Business Model Adopted, Purpose of Partnership, and Deal Financials
Table 13.1 ADC Technology: Most Likely Partners in North America
Table 13.2 ADC Technology: Likely Partners in North America
Table 13.3 ADC Technology: Less Likely Partners in North America
Table 13.4 ADC Technology: Most Likely Partners in Europe
Table 13.5 ADC Technology: Likely Partners in Europe
Table 13.6 ADC Technology: Less Likely Partners in Europe
Table 13.7 ADC Technology: Most Likely Partners in Asia-Pacific
Table 13.8 ADC Technology: Likely Partners in Asia-Pacific
Table 13.9 ADC Technology: Less Likely Partners in Asia-Pacific
Table 15.1 Antibody Drug Conjugates: Information on Developer, Stage of Development, Target Indication and Therapeutic Area
Table 15.2 Antibody Drug Conjugates: Information on Drug Candidates, Line of Treatment, Dosing Frequency and Type of Therapy
Table 15.3 Antibody Drug Conjugates: Information on Target Antigen, Antibody Isotype, Type of Linker (Cleavable and Non-Cleavable), Payload / Cytotoxin / Warhead Type of Payload
Table 15.4 Antibody-Drug Conjugate Developers: Information on Year of Establishment, Location of Headquarters (Country / Region), and Company Size
Table 23.1 Debiopharm: Company Snapshot
Table 23.2 Ajinomoto: Company Snapshot
Table 23.3 Abzena: Company Snapshot
Table 23.4 MedLink Therapeutics: Company Snapshot
Table 23.5 Merck KGaA: Company Snapshot
Table 23.6 Singzyme: Company Snapshot
Table 23.7 Ajinomoto: Company Snapshot
Table 23.8 Eucodis Bioscience: Company Snapshot
Table 23.9 Shanghai Miracogen: Company Snapshot
Table 23.10 NBE-Therapeutics: Company Snapshot
Table 23.11 Synaffix: Company Snapshot
Table 24.1 ADC Conjugation and Linker Technologies: Distribution by Type of Technology
Table 24.2 ADC Conjugation and Linker Technologies: Distribution by Availability of Licensing
Table 24.3 ADC Conjugation and Linker Technologies: Distribution by Generation of Technology
Table 24.4 ADC Conjugation Technologies: Distribution by Type of Conjugation
Table 24.5 ADC Conjugation Technologies: Distribution by Site Specificity
Table 24.6 ADC Conjugation Technologies: Distribution by Drug Antibody Ratio
Table 24.7 ADC Conjugation Technologies: Distribution by Compatible Linker
Table 24.8 ADC Conjugation Technologies: Distribution by Conjugation Chemistry
Table 24.9 ADC Conjugation Technologies: Distribution by Conjugation Site
Table 24.10 ADC Linker and Linker-Payload Technologies: Distribution by Type of Linker
Table 24.11 ADC Conjugation and Linker Technology Providers: Distribution by Year of Establishment
Table 24.12 ADC Conjugation and Linker Technology Providers: Distribution by Company Size
Table 24.13 ADC Conjugation and Linker Technology Providers: Distribution by Location of Headquarters
Table 24.14 ADC Conjugation and Linker Technology Providers: Distribution by Year of Establishment and Location of Headquarters
Table 24.15 Ajinomoto Bio-Pharma Services: Annual Revenues, FY 2021-H1 FY 2025 (JPY Billion)
Table 24.16 Novo Nordisk (parent company of Catalent Biologics): Annual Revenues, FY 2021-9M FY 2025 (DKK Billion)
Table 24.17 Mersana Therapeutics: Annual Revenues, FY 2021-9M FY 2025 (USD Million)
Table 24.18 Sutro Biopharma: Annual Revenues, Fy 2021-9M FY 2025 (USD Million)
Table 24.19 Heidelberg Pharma: Annual Revenues, FY 2021- 9M FY 2025 (EUR Million)
Table 24.20 Boehringer Ingelheim (parent company of NBE Therapeutics): Annual Revenues, FY 2021-H1 FY 2025 (EUR Billion)
Table 24.21 Lonza (parent company of Synaffix): Annual Revenues, FY 2021-9M FY 2025 (CHF Billion)
Table 24.22 LigaChem Biosciences: Annual Revenues, FY 2021-9M FY 2025 (KRW Billion)
Table 24.23 Patent Analysis: Distribution by Type of Patent
Table 24.24 Patent Analysis: Cumulative Distribution by Publication Year, 2021-2025
Table 24.25 Patent Analysis: Cumulative Distribution by Application Year, Pre-2019-2025
Table 24.26 Patent Analysis: Distribution of Type of Patent by Publication Year, 2021-2025
Table 24.27 Patent Analysis: Distribution by Patent Jurisdiction
Table 24.28 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 24.29 Leading Industry Players: Distribution by Number of Patents
Table 24.30 Leading Patent Assignees: Distribution by Number of Patents
Table 24.31 Patent Analysis: Distribution by Patent Age
Table 24.32 ADC Technologies: Patent Valuation
Table 24.33 Partnerships and Collaborations: Distribution by Year of Partnership
Table 24.34 Partnerships and Collaborations: Distribution by Type of Partnership
Table 24.35 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership, 2021-2025 (till November)
Table 24.36 Most Active Players: Distribution by Number of Partnerships
Table 24.37 Most Popular Technologies: Distribution by Number of Partnerships
Table 24.38 Partnerships and Collaborations: Local and International Agreements
Table 24.39 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 24.40 Business Models Analysis: Distribution by Purpose of Partnership
Table 24.41 Business Models Analysis: Distribution by Year and Purpose of Partnership, 2021-2025 (till November)
Table 24.42 Business Models Analysis: Distribution by Type of Business Model Adopted
Table 24.43 Business Models Analysis: Distribution by Deal Value
Table 24.44 Business Models Analysis: Distribution by Type of Business Model Adopted and Deal Value
Table 24.45 Most Active Players: Analysis by Number of Partnerships
Table 24.46 Lonza: Distribution by Purpose of Partnership
Table 24.47 Lonza: Distribution by Year of Partnership and Business Model Adopted
Table 24.48 LigaChem Biosciences: Distribution by Purpose of Partnership
Table 24.49 LigaChem Biosciences: Distribution by Year of Partnership and Business Model Adopted
Table 24.50 Debiopharm: Distribution by Purpose of Partnership
Table 24.51 Debiopharm: Distribution by Year of Partnership and Business Model Adopted
Table 24.52 Duality Biologics: Distribution by Purpose of Partnership
Table 24.53 IntoCell: Distribution by Purpose of Partnership
Table 24.54 IntoCell: Distribution by Year of Partnership and Business Model Adopted
Table 24.55 Antibody-Drug Conjugates: Distribution by Stage of Development
Table 24.56 Antibody-Drug Conjugates: Distribution by Target Indication
Table 24.57 Antibody-Drug Conjugates: Distribution by Therapeutic Area
Table 24.58 Antibody-Drug Conjugates: Distribution by Line of Treatment
Table 24.59 Antibody-Drug Conjugates: Distribution by Dosing Frequency
Table 24.60 Antibody-Drug Conjugates: Distribution by Type of Therapy
Table 24.61 Antibody-Drug Conjugates: Distribution by Target Antigen
Table 24.62 Antibody-Drug Conjugates: Distribution by Antibody Isotypes
Table 24.63 Antibody-Drug Conjugates: Distribution by Type of Linker (Cleavable / Non-Cleavable)
Table 24.64 Antibody-Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
Table 24.65 Antibody-Drug Conjugates: Distribution by Type of Payload
Table 24.66 Antibody-Drug Conjugate Developers: Distribution by Year of Establishment
Table 24.67 Antibody-Drug Conjugate Developers: Distribution by Company Size
Table 24.68 Antibody-Drug Conjugate Developers: Distribution by Location of Headquarters (Region)
Table 24.69 Antibody-Drug Conjugate Developers: Distribution by Location of Headquarters (Country)
Table 24.70 Most Active Players: Distribution by Number of Antibody-Drug Conjugates
Table 24.71 Global ADC Technology Market, Historical Trends (Since 2025) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario, 2025-2040 (USD Billion)
Table 24.72 ADC Technology Market: Distribution by Generation of Technology
Table 24.73 ADC Technology Market for Next-Generation Technologies: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.74 ADC Technology Market for Third-Generation Technologies: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.75 ADC Technology Market for Second-Generation Technologies: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.76 ADC Technology Market for First-Generation Technologies: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.77 ADC Technology Market: Distribution by Type of Conjugation
Table 24.78 ADC Technology Market for Chemical Conjugation: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.79 ADC Technology Market for Chemoenzymatic Conjugation: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.80 ADC Technology Market for Enzymatic Conjugation: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.81 ADC Technology Market: Distribution by Type of Linker
Table 24.82 ADC Technology Market for Cleavable Linkers: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.83 ADC Technology Market for Non-Cleavable Linkers: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.84 ADC Technology Market: Distribution by Geographical Regions
Table 24.85 ADC Technology Market in North America: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.86 ADC Technology Market in Europe: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.87 ADC Technology Market in Asia-Pacific: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.88 ADC Technology Market in Latin America: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Table 24.89 ADC Technology Market in Middle East and North Africa: Historical Trends (Since 2025) and Forecasted Estimates (Till 2040) (USD Billion)
Please reach out to our team for the details.